Ignite Creation Date:
2024-05-06 @ 12:15 AM
Last Modification Date:
2024-10-26 @ 10:46 AM
Study NCT ID:
NCT01524926
Status:
COMPLETED
Last Update Posted:
2023-12-11
First Post:
2012-01-24
Brief Title:
CREATE Cross-tumoral Phase 2 With Crizotinib
Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC
Organization:
European Organisation for Research and Treatment of Cancer - EORTC
Study Overview
Official Title:
Cross-tumoral Phase 2 Clinical Trial Exploring Crizotinib PF-02341066 in Patients With Advanced Tumors Induced by Causal Alterations of ALK andor MET CREATE
Status:
COMPLETED
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CREATE
Brief Summary:
The study will primarily assess the antitumor activity of crizotinib in a variety of tumors with alterations in ALK andor MET pathways The targeted patient population will include patients with tumors harboring specific alterations leading to ALK andor MET activation where tyrosine kinase inhibitors against these targets have not yet been adequately explored
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2011-001988-52 | EUDRACT_NUMBER | None | None |